Given that the regulatory role of UBE2C and PLK1 in the cell cycle may be due to the downregulation of CDK1 and CDK4/6, along with their aberrant activation and positive correlation in pan-cancer tissues, coupled with their involvement in the manifestation of pan-cancer phenotypes, targeting both UBE2C and PLK1 may represent a promising therapeutic strategy. This evidence concerns the gene CDK1 and cancer.